2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T79a9,

Summary Table

Feature	Detail
Risk Factors	Male sex (2:1 ratio), age 50 to 70 years, smoking, obesity, Von Hippel-Lindau (VHL) syndrome, acquired cystic kidney disease in dialysis patients, long-standing hypertension, family history of RCC, occupational exposure to cadmium or trichloroethylene
Etiology	Arises from the epithelial cells of the renal tubule. The most common subtype (clear cell, ~75%) is driven by loss of the VHL tumor suppressor gene on chromosome 3p. Papillary and chromophobe subtypes have distinct molecular drivers.
Patient Presentation	Often incidental on cross-sectional imaging. The classic triad of flank pain, gross hematuria, and palpable abdominal mass is present in only ~10% of cases and usually signals advanced disease. Constitutional symptoms include weight loss, fatigue, fever of unknown origin, and night sweats.
Classic Physical Exam	Palpable flank or abdominal mass, left-sided varicocele that does not decompress when the patient lies supine (due to left renal vein obstruction by tumor thrombus), new-onset hypertension, lower extremity edema (IVC obstruction)
Key Diagnostic Results	CT abdomen/pelvis with IV contrast showing an enhancing solid renal mass; urinalysis with hematuria; CBC showing polycythemia (ectopic erythropoietin); serum calcium elevated (PTHrP secretion); elevated LDH and ESR; hepatic function panel derangement without liver metastases (Stauffer syndrome)
Management	Localized: partial nephrectomy (tumors ≤4 cm) or radical nephrectomy. Metastatic: cytoreductive nephrectomy plus systemic therapy with VEGF-targeted tyrosine kinase inhibitors (sunitinib, cabozantinib) or immune checkpoint inhibitor combinations (nivolumab + ipilimumab). RCC is resistant to conventional chemotherapy and radiation therapy.
Keywords	"Classic triad," "left-sided varicocele that does not decompress supine," "cannonball metastases," "Stauffer syndrome," "paraneoplastic polycythemia," "enhancing renal mass," "clear cell," "VHL gene," "resistant to chemo and radiation"

1. Pathophysiology

Renal cell carcinoma originates from the epithelial lining of the proximal convoluted tubule. Understanding the molecular pathway behind the most common subtype, clear cell RCC, is essential because it directly explains both the tumor's behavior and the rationale for targeted therapy.

The VHL gene on chromosome 3p encodes a protein that is part of an E3 ubiquitin ligase complex. Under normal oxygen conditions, this complex tags hypoxia-inducible factor (HIF) for proteasomal degradation. When VHL function is lost, whether through germline mutation (as in VHL syndrome) or sporadic biallelic inactivation, HIF accumulates even in normoxic conditions. Accumulated HIF translocates to the nucleus and drives transcription of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), erythropoietin (EPO), and transforming growth factor-alpha (TGF-alpha). This explains the hallmark features of clear cell RCC: it is a highly vascular tumor (VEGF overexpression leads to rich neovasculature, which is why it enhances avidly on contrast CT), and it produces ectopic hormones that generate paraneoplastic syndromes.

The polycythemia seen in RCC is a direct consequence of ectopic EPO production driven by HIF upregulation. The hypercalcemia results from tumor secretion of parathyroid hormone-related peptide (PTHrP), which mimics PTH action on bone and kidney. Hypertension can occur through ectopic renin secretion by the tumor, or through renal artery compression. The peculiar Stauffer syndrome, a paraneoplastic hepatic dysfunction without liver metastases, is mediated by tumor secretion of IL-6, which causes hepatic inflammation and cholestasis. Stauffer syndrome reverses after nephrectomy; if it recurs postoperatively, suspect tumor recurrence.

The left-sided varicocele is a classic exam finding. The left gonadal vein drains into the left renal vein (unlike the right, which drains directly into the IVC). When tumor thrombus extends into the left renal vein, it obstructs gonadal venous return, producing a varicocele. The key discriminator from an idiopathic varicocele is that a tumor-related varicocele does not decompress when the patient assumes a supine position.

RCC has a strong propensity for venous invasion, extending as tumor thrombus through the renal vein and into the inferior vena cava, sometimes reaching the right atrium. This venous tropism, combined with hematogenous spread, accounts for the pattern of "cannonball" pulmonary metastases, which are large, well-circumscribed, bilateral nodules on chest X-ray.

2. Classification and Clinical Manifestation

Subtype	Frequency	Cell of Origin	Molecular Driver	Prognosis	Key Feature
Clear Cell	75-80%	Proximal tubule epithelium	VHL gene loss (chromosome 3p)	Variable; most aggressive when high grade	Cells with clear cytoplasm (lipid and glycogen content); highly vascular
Papillary (Type 1)	10-15%	Proximal tubule epithelium	MET proto-oncogene activation (chromosome 7)	Better than clear cell	Papillary architecture; often multifocal and bilateral
Papillary (Type 2)	Subset of papillary	Proximal tubule epithelium	Fumarate hydratase (FH) loss (hereditary leiomyomatosis and RCC syndrome)	Worse than Type 1	Higher nuclear grade; more aggressive
Chromophobe	5%	Intercalated cells of collecting duct	Multiple chromosomal losses (chromosomes 1, 2, 6, 10, 13, 17, 21)	Best prognosis of all subtypes	Large pale cells with perinuclear halo; associated with Birt-Hogg-Dube syndrome
Collecting Duct (Bellini)	<1%	Principal cells of medullary collecting duct	Various	Very poor	Presents at advanced stage; medullary location
Medullary	Rare	Collecting duct	Associated with sickle cell trait or disease	Extremely poor	Almost exclusively in young patients with sickle cell trait

TNM Staging

Stage	T Classification	Description	Clinical Relevance
I	T1 (≤7 cm, confined to kidney)	T1a ≤4 cm, T1b 4-7 cm	Partial nephrectomy for T1a; radical or partial for T1b
II	T2 (>7 cm, confined to kidney)	T2a 7-10 cm, T2b >10 cm	Radical nephrectomy
III	T3 or N1	Extends into renal vein/IVC (T3a/T3b/T3c) or perinephric fat, or single regional lymph node	Radical nephrectomy with IVC thrombectomy if needed
IV	T4 or M1	Invades beyond Gerota fascia, or distant metastases	Cytoreductive nephrectomy + systemic therapy

Paraneoplastic Syndromes of RCC

Syndrome	Mediator	Clinical Finding	Exam Significance
Polycythemia	Ectopic erythropoietin	Elevated hemoglobin/hematocrit	Paradoxical; most renal tumors cause anemia, but RCC causes polycythemia
Hypercalcemia	PTHrP	Elevated serum calcium, stones, bone pain, confusion	Most common paraneoplastic feature of RCC
Hypertension	Ectopic renin	New-onset or refractory hypertension	Consider RCC in workup of secondary hypertension
Stauffer Syndrome	IL-6	Elevated ALP, transaminases, prolonged PT, hepatosplenomegaly WITHOUT liver metastases	Resolves after nephrectomy; recurrence = tumor recurrence
Cushing Syndrome	Ectopic ACTH	Moon facies, central obesity, striae, hyperglycemia	Rare but tested

3. Diagnostic Workup

Test	Role	Key Finding
CT abdomen/pelvis with IV contrast	Best initial test for characterizing a renal mass	Solid, enhancing mass (>15-20 HU enhancement); distinguishes cyst from solid tumor
CT chest	Staging (lung metastases)	"Cannonball" bilateral pulmonary nodules
MRI abdomen	Alternative if contrast allergy or for IVC thrombus evaluation	Better soft tissue delineation; defines extent of venous thrombus
Renal ultrasound	Often the initial study that incidentally detects the mass	Solid hyperechoic or hypoechoic mass; cannot reliably characterize
Urinalysis	Screening	Microscopic or gross hematuria
CBC	Paraneoplastic evaluation	Polycythemia (elevated Hgb/Hct) or anemia of chronic disease
BMP/CMP	Paraneoplastic evaluation	Hypercalcemia, elevated creatinine, liver function derangement
LDH, ESR	Prognostic markers	Elevated in advanced disease
Renal biopsy	NOT routine for classic enhancing mass	Reserved for indeterminate lesions or when tissue diagnosis is needed before systemic therapy in unresectable disease

The vast majority of renal cell carcinomas are now discovered incidentally during cross-sectional imaging performed for unrelated complaints. When an incidental renal mass is found on ultrasound, the next step is a CT abdomen and pelvis with IV contrast, which is the best initial test for characterizing a renal mass. The hallmark finding is a solid, enhancing renal mass that increases by more than 15 to 20 Hounsfield units after contrast administration. Enhancement distinguishes a solid neoplasm from a simple cyst (which does not enhance) and from a hemorrhagic or complex cyst (which may have high attenuation on non-contrast CT but does not enhance).

If the patient has a contrast allergy or renal insufficiency, MRI with gadolinium is the alternative. MRI is also the preferred study for evaluating the extent of tumor thrombus in the renal vein and IVC, which directly affects surgical planning.

A CT of the chest is obtained for staging, because the lungs are the most common site of distant metastasis. The classic appearance is "cannonball" metastases: large, round, bilateral pulmonary nodules. Other common metastatic sites include bone, liver, brain, and the contralateral kidney.

A critical exam pearl: do not biopsy a classic enhancing renal mass. When imaging is characteristic for RCC (solid, enhancing, no fat), the standard of care is to proceed directly to surgical resection without biopsy. Biopsy is reserved for situations where the diagnosis is uncertain (indeterminate imaging), when the patient is not a surgical candidate, or when tissue is needed to guide systemic therapy selection in metastatic disease.

Laboratory workup should include a complete blood count (look for paradoxical polycythemia from ectopic EPO, or anemia), basic metabolic panel (hypercalcemia from PTHrP), liver function tests (Stauffer syndrome), urinalysis (hematuria), and LDH (prognostic). An elevated ESR in the setting of a renal mass is another clue.

For lesions that contain macroscopic fat on CT (negative Hounsfield units), the diagnosis is almost always angiomyolipoma, not RCC, and this distinction is a frequent test question.

4. Management and Treatment

Clinical Scenario	Treatment	Details
Localized, T1a (≤4 cm)	Partial nephrectomy (nephron-sparing surgery)	Preferred over radical nephrectomy; equivalent oncologic outcome with preservation of renal function
Localized, T1b-T2 (>4 cm, confined)	Radical nephrectomy (or partial if technically feasible)	Includes kidney, perirenal fat, Gerota fascia; ipsilateral adrenalectomy only if imaging shows adrenal involvement
T3 with venous thrombus	Radical nephrectomy + IVC thrombectomy	May require cardiopulmonary bypass if thrombus extends to right atrium
Metastatic, good risk	Cytoreductive nephrectomy + immune checkpoint combination: nivolumab + ipilimumab	First-line for intermediate/poor risk per IMDC criteria
Metastatic, favorable risk	VEGF-TKI monotherapy: sunitinib or pazopanib	Oral agents; monitor for hypertension, hand-foot syndrome, thyroid dysfunction
Metastatic, subsequent lines	Cabozantinib, axitinib + pembrolizumab, lenvatinib + pembrolizumab, everolimus	Choice depends on prior therapy and IMDC risk group
Adjuvant (high-risk post-nephrectomy)	Pembrolizumab for 1 year	For clear cell RCC with high risk of recurrence (per KEYNOTE-564 trial)
Small renal mass in elderly/comorbid	Active surveillance	Serial imaging; intervention if growth documented

Localized Disease

The cornerstone of curative treatment for localized RCC is surgical resection. For tumors ≤4 cm (T1a), the standard of care is partial nephrectomy (also called nephron-sparing surgery). This approach provides equivalent cancer control to radical nephrectomy while preserving renal parenchyma and reducing the long-term risk of chronic kidney disease. This is a frequently tested concept: the exam will present a small, enhancing renal mass and expect you to choose partial nephrectomy over radical nephrectomy.

For tumors >4 cm but still organ-confined, radical nephrectomy is typically performed, though partial nephrectomy is preferred when technically feasible to preserve nephron mass. Radical nephrectomy includes removal of the kidney, perirenal fat, and Gerota fascia. Ipsilateral adrenalectomy is no longer routine unless preoperative imaging shows adrenal involvement, which is another important point for the exam.

Lymph node dissection in RCC remains controversial. It is generally performed when lymphadenopathy is identified on preoperative imaging but is not routinely done for clinically node-negative disease.

A key exam principle: RCC is resistant to conventional cytotoxic chemotherapy and to external beam radiation therapy. This means the exam will never present chemotherapy (e.g., cisplatin, doxorubicin) as a correct treatment for RCC, and radiation is used only for palliation of symptomatic bone or brain metastases.

Metastatic Disease

For patients with metastatic clear cell RCC, treatment is guided by the IMDC (International Metastatic RCC Database Consortium) risk stratification, which incorporates six adverse prognostic factors: Karnofsky performance status <80%, time from diagnosis to treatment <1 year, hemoglobin below lower limit of normal, corrected calcium above upper limit of normal, neutrophil count above upper limit of normal, and platelet count above upper limit of normal.

For intermediate and poor-risk patients (1 or more adverse factors), the first-line regimen is nivolumab (3 mg/kg IV every 3 weeks) combined with ipilimumab (1 mg/kg IV every 3 weeks) for 4 cycles, followed by nivolumab maintenance (480 mg IV every 4 weeks). Alternative first-line combinations include axitinib + pembrolizumab or lenvatinib + pembrolizumab.

For favorable-risk patients, VEGF-targeted TKI monotherapy with sunitinib (50 mg orally daily, 4 weeks on / 2 weeks off) or pazopanib (800 mg orally daily, continuous) remains an option, though combination immunotherapy-TKI regimens are increasingly preferred.

Cytoreductive nephrectomy (removing the primary tumor in the setting of metastatic disease) may be performed in selected patients with good performance status and limited metastatic burden, typically before initiating systemic therapy.

For subsequent lines, cabozantinib (a multi-target TKI that also inhibits MET and AXL) and everolimus (an mTOR inhibitor) are used. The key side effects to know for the exam are: sunitinib causes hand-foot syndrome, hypertension, hypothyroidism, and diarrhea; nivolumab/ipilimumab causes immune-mediated colitis, hepatitis, pneumonitis, and endocrinopathies (hypophysitis, thyroiditis, adrenal insufficiency).

5. Differential Diagnosis and Distractors

Differential	Why It Is Similar	Key Discriminator
Angiomyolipoma (AML)	Both present as renal masses on imaging; AML can also cause flank pain and hemorrhage	AML contains macroscopic fat (negative Hounsfield units on CT). Associated with tuberous sclerosis complex (TSC). RCC does NOT contain fat on imaging.
Oncocytoma	Benign solid renal mass; can be large and mimic RCC on imaging	Classically shows a central stellate scar on contrast CT. Cannot be reliably distinguished from chromophobe RCC on imaging alone; diagnosis is often made postoperatively.
Transitional Cell Carcinoma (Urothelial Carcinoma of the Renal Pelvis)	Both can cause hematuria and a renal mass	TCC presents as a filling defect within the renal pelvis/collecting system on CT urogram, not as a solid cortical mass. Associated with smoking, aniline dyes, cyclophosphamide, and phenacetin.
Simple Renal Cyst	Extremely common incidental finding on imaging	Simple cysts are well-circumscribed, anechoic (on US), and do NOT enhance with contrast. Bosniak classification guides management.
Renal Abscess	Can present with flank pain, fever, and a renal mass	Clinical context includes UTI symptoms, fever, leukocytosis, and pyuria. CT shows rim-enhancing fluid collection, not a solid enhancing mass.
Wilms Tumor (Nephroblastoma)	Large renal mass with hematuria	Wilms tumor occurs in children aged 2 to 5 years. RCC is an adult malignancy. Wilms is associated with WAGR syndrome, Beckwith-Wiedemann, and Denys-Drash.
Renal Lymphoma	Bilateral renal masses or diffuse infiltration	Usually occurs in the setting of known systemic lymphoma; renal involvement is almost always secondary. Homogeneous, hypoenhancing masses without necrosis.
Metastasis to Kidney	Solid renal mass in a patient with known primary malignancy elsewhere	Most common primaries that metastasize to the kidney are lung, breast, and melanoma. Usually small, bilateral, and multiple. Clinical context of a known primary elsewhere is the key.

6. Traps and High-Yield Pearls

The most common way students lose points on RCC questions is by failing to recognize its paraneoplastic presentations. A vignette may not mention a renal mass at all. Instead, it will present a middle-aged male smoker with unexplained polycythemia, hypercalcemia, or hepatic dysfunction (elevated alkaline phosphatase with a normal hepatic ultrasound), and the question will ask for the most likely underlying diagnosis. The correct answer is RCC, and the clue is the constellation of paraneoplastic findings. Remember: polycythemia in a patient with a renal mass is RCC until proven otherwise, because most other renal pathology causes anemia, not polycythemia.

A second trap involves the left-sided varicocele. Exam questions will describe a man presenting with a new left scrotal swelling. The discriminating detail is that the varicocele persists in the supine position. An idiopathic varicocele decompresses when the patient lies flat because gravity no longer pools blood in the pampiniform plexus. A varicocele caused by left renal vein obstruction from tumor thrombus does not decompress, because the obstruction is mechanical and position-independent. If you see a non-decompressing left varicocele, the next step is imaging of the left kidney.

A third common error is ordering a biopsy for a classic enhancing renal mass. Students who are trained to think "tissue is the diagnosis" may select percutaneous biopsy. However, for a solid, enhancing, non-fat-containing renal mass on CT, the standard of care is proceeding directly to surgery. Biopsy is only appropriate for indeterminate lesions, when the patient is not a surgical candidate, or when tissue is needed to guide systemic therapy.

Fourth, remember that RCC is resistant to chemotherapy and radiation. Any answer choice offering cisplatin-based regimens, doxorubicin, or external beam radiation as primary treatment for RCC is a distractor. The only role for radiation in RCC is palliation of symptomatic metastases (bone pain, brain metastases).

Finally, know the difference between Stauffer syndrome and true hepatic metastasis. Stauffer syndrome is a paraneoplastic phenomenon (IL-6 mediated) causing liver function test abnormalities and hepatosplenomegaly in the absence of liver metastases. It reverses after nephrectomy. If a post-nephrectomy patient develops recurrent liver function derangement, this signals tumor recurrence, not progression of liver disease.

The core competency being tested across RCC questions is your ability to integrate clinical, laboratory, and imaging data to recognize a diagnosis that often presents indirectly through its paraneoplastic and vascular complications, and to apply the correct management sequence: imaging characterization first, surgical resection for localized disease (partial over radical for small tumors), and targeted or immunotherapy (never chemotherapy) for metastatic disease.

1e:["$","$L2d",null,{"article":{"id":"4fd50c79-8c7f-4bea-9414-a7a07e2bf5fb","title":"Karsinoma Sel Renal","content":"$2e","category":"Uronefrologi","created_at":"2026-08-11T08:36:21.823569+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]